Payment overview · 2025
General Payments
$1,667.90
48 reported records · 12 companies
Healthcare provider profile · identity verified
Thuyvy Le, DO
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JOSE, CA · NPI 1841751088
Verified facts
What the public records show
CMS Open Payments records show Thuyvy Le, DO received $1,667.90 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $624.09 | 37.4% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $262.39 | 15.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.82 | 12.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.68 | 9.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $127.47 | 7.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.36 | 6.1% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.72 | 2.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.35 | 2.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.10 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.28 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.85 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.79 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,667.90 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $240.04 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $237.54 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $208.82 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $198.31 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $153.12 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $127.47 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.83 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.64 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.64 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.23 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $36.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 22 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 309 |
| Amlodipine Besylate | Amlodipine Besylate | 396 | 216 |
| Losartan Potassium | Losartan Potassium | 394 | 225 |
| Metformin Hcl | Metformin Hcl | 238 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 100 |
| Alendronate Sodium | Alendronate Sodium | 172 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 93 |
| Jardiance | Empagliflozin | 160 | 62 |
| Gabapentin | Gabapentin | 145 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 61 |
| Lisinopril | Lisinopril | 89 | 48 |
| Azithromycin | Azithromycin | 76 | 71 |
| Donepezil Hcl | Donepezil Hcl | 73 | 37 |
| Simvastatin | Simvastatin | 66 | 43 |
| Furosemide | Furosemide | 62 | 23 |
| Eliquis | Apixaban | 61 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 49 |
| Trazodone Hcl | Trazodone Hcl | 57 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 27 |
| Torsemide | Torsemide | 55 | 30 |
| Carvedilol | Carvedilol | 53 | 27 |
| Januvia | Sitagliptin Phosphate | 53 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 35 |
| Farxiga | Dapagliflozin Propanediol | 50 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 22 |
| Tradjenta | Linagliptin | 50 | 19 |
| Omeprazole | Omeprazole | 47 | 40 |
| Glipizide | Glipizide | 45 | 26 |
| Atenolol | Atenolol | 44 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 19 |
| Metformin Hcl Er | Metformin Hcl | 37 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 18 |
| Allopurinol | Allopurinol | 36 | 29 |
| Telmisartan | Telmisartan | 36 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 26 |
| Vascepa | Icosapent Ethyl | 34 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | 14 |
| Meloxicam | Meloxicam | 29 | 26 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 17 |
| Mirtazapine | Mirtazapine | 28 | 14 |
| Estradiol | Estradiol | 27 | 16 |
| Famotidine | Famotidine | 27 | 17 |
| Loperamide | Loperamide Hcl | 27 | 22 |
| Montelukast Sodium | Montelukast Sodium | 26 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Celecoxib | Celecoxib | 23 | 18 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Megestrol Acetate | Megestrol Acetate | 22 | 16 |
| Benzonatate | Benzonatate | 21 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 17 |
| Methimazole | Methimazole | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 19 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | 14 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Finasteride | Finasteride | 16 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Prolia | Denosumab | 13 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,667.90 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, Flector, GARDASIL 9, GVOKE HYPOPEN, KISUNLA, Kerendia, Licart, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tirosint, Wegovy, ZENPEP, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error